Clinical data | |
---|---|
Other names | primaquine phosphate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607037 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 96%[1] |
Metabolism | Liver |
Elimination half-life | 6 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.001.807 |
Chemical and physical data | |
Formula | C15H21N3O |
Molar mass | 259.353 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Primaquine is a medication used to treat and prevent malaria and to treat Pneumocystis pneumonia.[2] Specifically it is used for malaria due to Plasmodium vivax and Plasmodium ovale along with other medications and for prevention if other options cannot be used.[2] It is an alternative treatment for Pneumocystis pneumonia together with clindamycin.[2][3] It is taken by mouth.[2]
Common side effects include nausea, vomiting, and stomach cramps.[2][4] Primaquine should not be given to people with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of red blood cell breakdown.[4] It is often recommended that primaquine not be used during pregnancy.[5][6] It may be used while breastfeeding if the baby is known not to have G6PD deficiency.[6] The mechanisms of action is not entirely clear but is believed to involve effects on the malaria parasites' DNA.[2]
Primaquine was first made in 1946.[3] It is on the World Health Organization's List of Essential Medicines.[7][8] It is available as a generic medication.[2]